Exelixis (EXEL)

Healthcare · Biotechnology
$58.33 -0.88% on the day Market cap $13.9B 52-week range $33.76 to $61.14 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
2% a year for 10 years

At a market value of $13.9B, Exelixis's free cash flow of $876M (fiscal 2025) would need to grow about 2% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Exelixis's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price2.0% a year
Free cash flow, last 9 years17.5% a year
Revenue, same period31.9% a year
Price to free cash flow15.9x

Fundamental grade

B

Five factors scored 1 to 9 from EXEL's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation6
Profitability9
Growth6
Financial health8
Cash efficiency9

Key numbers

P/E (trailing)18.3x
P/E (forward)18.1x
Price / free cash flow16.5x
EV / EBITDA12.2x
Price / sales5.71x
Price / book7.41x
Revenue growth+10.6%
Operating margin39.9%
Net margin35.3%
Return on equity46.7%
Dividend yield—
Debt / equity0.35x

Results from SEC filings

Fiscal years, from Exelixis's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$1.4B$1.6B$1.8B$2.2B$2.3B
Net income$231M$182M$208M$521M$783M
Free cash flow$347M$335M$293M$672M$876M
EPS (diluted)$0.72$0.56$0.65$1.76$2.78
Operating margin20.0%12.5%9.3%27.9%37.6%

Where the revenue comes from

Revenue by products, fiscal 2025.

Net product revenues$2.1B91%
Collaboration services revenues$197M9%

Superinvestors who own EXEL

From each investor's latest 13F filing (what a 13F shows). 4 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Tom Steyer
Farallon Capital Management LLC
Added $733M3.4%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $599M0.21%Q2 2026
Joel Greenblatt
Gotham Asset Management
Trimmed $49M0.11%Q2 2026
Jean-Marie Eveillard
First Eagle Investment Management
Held $544,1000.00%Q2 2026

Insider buying

Open-market purchases by Exelixis's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of EXEL in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when EXEL trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Exelixis's stock price imply?

At a market value of $13.9B, Exelixis would need its free cash flow to grow about 2% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 18% a year.

Are Exelixis insiders buying the stock?

No open-market insider purchases of EXEL in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Exelixis?

4 of the superinvestors Investingly tracks hold EXEL in their latest 13F, including Tom Steyer, Cliff Asness, Joel Greenblatt.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.